Lukeman Kharrat
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Lukeman Kharrat has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
David Pride
Department of Pathology, University of California San Diego, San Diego, USA
1 shared publicationDouglas J. Conrad
Division of Pulmonary, Critical Care, and Sleep Medicine, San Diego, USA
1 shared publication- Dwayne R. Roach
Department of Biology, San Diego State University
1 shared publication Jennifer A. Melendez
Department of Biology, San Diego State University, San Diego, USA
1 shared publication- Kevin Champagne-Jorgensen
Department of Immunology, University of Toronto, Toronto, Canada
1 shared publication - Tiffany Luong
Department of Biology, San Diego State University, San Diego, CA, USA
1 shared publication
Latest Publications
- Open Access
- 11 February 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Ecological partitioning enables phage–antibiotic cooperation in a human Pseudomonas infection
Bacteriophage–antibiotic coadministration is increasingly used for refractory infections, yet the in vivo interactions among phages, bacteria, antibiotics, and host immunity remain poorly defined. We report a longitudinal, multiomic case analysis of a male in his seventies with cystic fibrosis (CF) experiencing an acute-on-chronic pulmonary exacerbation caused by multidrug-resistant (MDR) Pseudomonas aeruginosa . After colistin discontinuation due to nephrotoxicity, ciprofloxacin was initiated, with an intravenous two-phage cocktail introduced days later. Distinct mucoid and nonmucoid bacterial subpopulations associated differentially with antibiotic versus phage exposure, consistent with nonoverlapping selective pressures. Phage activity was temporally constrained, with one phage dominating early bacterial and genomic signals before attenuating after approximately seven days, despite continued genomic detectability. In contrast, the second phage showed no evidence of productive activity. This asymmetry coincided with phage-reactive humoral immunity: pre-existing IgM was associated with lack of recoverability of one phage, while treatment-associated IgM emergence temporally tracked attenuation of the dominant phage. Although phage-resistant variants arose during therapy, they showed limited expansion relative to susceptible populations. These findings define a mechanistic framework—chemobiotherapy—in which chemical and biological antimicrobials coordinate through ecological and immunologic complementarity rather than direct pharmacologic synergy.
- 11 February 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Open AccessEcological partitioning enables phage–antibiotic cooperation in a human Pseudomonas infection
Bacteriophage–antibiotic coadministration is increasingly used for refractory infections, yet the in vivo interactions among phages, bacteria, antibiotics, and host immunity remain poorly defined. We report a longitudinal, multiomic case analysis of a male in his seventies with cystic fibrosis (CF) experiencing an acute-on-chronic pulmonary exacerbation caused by multidrug-resistant (MDR) Pseudomonas aeruginosa . After colistin discontinuation due to nephrotoxicity, ciprofloxacin was initiated, with an intravenous two-phage cocktail introduced days later. Distinct mucoid and nonmucoid bacterial subpopulations associated differentially with antibiotic versus phage exposure, consistent with nonoverlapping selective pressures. Phage activity was temporally constrained, with one phage dominating early bacterial and genomic signals before attenuating after approximately seven days, despite continued genomic detectability. In contrast, the second phage showed no evidence of productive activity. This asymmetry coincided with phage-reactive humoral immunity: pre-existing IgM was associated with lack of recoverability of one phage, while treatment-associated IgM emergence temporally tracked attenuation of the dominant phage. Although phage-resistant variants arose during therapy, they showed limited expansion relative to susceptible populations. These findings define a mechanistic framework—chemobiotherapy—in which chemical and biological antimicrobials coordinate through ecological and immunologic complementarity rather than direct pharmacologic synergy.